Cellyan Biotechnology (HKPD) Common Equity (2024 - 2026)
Cellyan Biotechnology (HKPD) posted quarterly Common Equity of $5.1 million for Q3 2025, down 3.9% year-over-year from $5.4 million in Q3 2024, and up 3.08% quarter-over-quarter from $5.0 million in Q1 2025.
Cellyan Biotechnology (HKPD) Common Equity (2024 - 2026) Analysis & Trends
Cellyan Biotechnology (HKPD) has reported Common Equity for 2 consecutive years, with $5.1 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Common Equity fell 3.9% year-over-year to $5.1 million; the TTM figure through Sep 2025 stood at $5.1 million (down 3.9% YoY), while the FY2025 annual figure was $5.0 million, up 17.31% from the prior year.
- Common Equity advanced to $5.1 million in Q3 2025 per HKPD's latest filing, from $5.0 million in the prior quarter.
- Across five years, Common Equity topped out at $5.4 million in Q3 2024 and bottomed at $4.3 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 102.57 Bn | 97.41 Bn | 3.69 Bn | -4.24 Bn |
| 2 | Cencora | 61.35 Bn | 58.53 Bn | 3.61 Bn | 3.24 Bn |
| 3 | Cardinal Health | 54.15 Bn | 49.30 Bn | 2.56 Bn | -2.88 Bn |
| 4 | Henry Schein | 10.05 Bn | 9.89 Bn | 1.10 Bn | 3.82 Bn |
| 5 | Akso Health | 671.90 Mn | 671.70 Mn | - | 180.93 Mn |
| 6 | Edap Tms | 154.62 Mn | 133.07 Mn | 7.34 Mn | -3.23 Mn |
| 7 | Accendra Health | 90.69 Mn | 83.04 Mn | 263.41 Mn | -550.94 Mn |
| 8 | 111 | 31.31 Mn | -27.44 Mn | 18.18 Mn | -110.00 Mn |
| 9 | Cosmos Health | 13.28 Mn | 10.84 Mn | 1.51 Mn | 20.67 Mn |
| 10 | Cellyan Biotechnology | 6.70 Mn | 6.48 Mn | - | 9.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.63 Mn |
| Sep 30, 2025 | 5.14 Mn |
| Mar 31, 2025 | 4.99 Mn |
| Sep 30, 2024 | 5.35 Mn |
| Mar 31, 2024 | 4.25 Mn |